Oral agent therapy in the treatment of type 2 diabetes.

Oral agent therapy in the treatment of type 2 diabetes.

Detalhes bibliográficos
Principais autores:	Feinglos, M, Bethel, M
Formato:	Conference item
Publicado em:	1999

Registros relacionados

Treatment of diabetes mellitus: implications of the use of oral agents.
por: Rao, S, et al.
Publicado em: (1999)

Basal insulin therapy in type 2 diabetes.
por: Bethel, M, et al.
Publicado em: (2005)

Treatment of type 2 diabetes mellitus.
por: Feinglos, M, et al.
Publicado em: (1998)

Therapy of type 2 diabetes, cardiovascular death, and the UGDP.
por: Feinglos, M, et al.
Publicado em: (1999)

Insulin analogues: new therapies for type 2 diabetes mellitus.
por: Bethel, M, et al.
Publicado em: (2002)

Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.
por: Feinglos, M, et al.
Publicado em: (2005)

In-hospital management of type 2 diabetes mellitus.
por: Lien, L, et al.
Publicado em: (2004)

Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
por: Bethel, M, et al.
Publicado em: (2007)

Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes.
por: Sloan, F, et al.
Publicado em: (2004)

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
por: Feinglos, M, et al.
Publicado em: (1997)

Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients.
por: Bethel, M, et al.
Publicado em: (2007)

Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus
por: Şazi İmamoğlu
Publicado em: (2021-01-01)

Diabetes on a cardiovascular ward: adherence to current recommendations.
por: Bethel, M, et al.
Publicado em: (2004)

Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
por: Tatiana Ivanovna Romantsova, et al.
Publicado em: (2010-03-01)

Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
por: Min Kyong Moon, et al.
Publicado em: (2017-10-01)

Depressed mood is a factor in glycemic control in type 1 diabetes.
por: Tilburg, V, et al.
Publicado em: (2001)

The growing burden of diabetes mellitus in the US elderly population.
por: Sloan, F, et al.
Publicado em: (2008)

Differences in persistence by class of oral therapy for the treatment of type 2 diabetes
por: McGovern, AP, et al.
Publicado em: (2016)

Addition of insulin to oral therapy in type 2 diabetes - Reply
por: Holman, R, et al.
Publicado em: (2008)

Assessment of Type 2 Diabetes Patients’ Knowledge of Oral Hypoglycemic Agents
por: Milica Paut Kusturica, et al.
Publicado em: (2020-01-01)

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
por: Dawed AY, et al.
Publicado em: (2016-04-01)

Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
por: Hye Soon Kim
Publicado em: (2024-09-01)

Effect of oral hypoglycaemic agents on bone metabolism in patients with type 2 diabetes mellitus
por: B. Siddhartha Kumar, et al.
Publicado em: (2012-04-01)

Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan
por: Mir Iftikhar Bashir, et al.
Publicado em: (2012-01-01)

Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents
por: R Pollock, et al.
Publicado em: (2010-10-01)

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
por: Holman, R, et al.
Publicado em: (2007)

The availability of inhaled human insulin may lead to a greater acceptance of insulin therapy in European type 2 diabetes patients failing on diet and/or oral agent therapy
por: Freemantle, N, et al.
Publicado em: (2006)

The impact of Ramadan fasting on glucose variability in type 2 diabetes mellitus patients on oral anti diabetic agents.
por: Dante S Harbuwono, et al.
Publicado em: (2020-01-01)

Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes
por: Matthews, DR, et al.
Publicado em: (2012)

Effects of short-term combination therapy with insulin on glycoregulation and insulin secretory function in patients with type 2 diabetes mellitus and secondary failure to treatment with oral antidiabetic agents
por: Gabrijela Malešević, et al.
Publicado em: (2019-07-01)

The impact of disease stage, indicated by number of previous oral antidiabetic agents, on the clinical benefits of liraglutide in the treatment of type 2 diabetes
por: Garber, A, et al.
Publicado em: (2011)

Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
por: Ivan Ivanovich Dedov, et al.
Publicado em: (2010-03-01)

Effect of treatment intensification on glycemic control in patients with subcontrolled type 2 diabetes who failed on two oral antidiabetic agents
por: Malinda S. Tan, et al.
Publicado em: (2023-01-01)

Factors Responsible for Delay in Initiation of Insulin Treatment in Type-2 Diabetes Mellitus Patients with Secondary Failure of Oral Hypoglycemic Agents
por: Muhammad Mujeeb Khan
Publicado em: (2018-01-01)

Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study.
por: Calvert, M, et al.
Publicado em: (2007)

Oral tolerance therapy in type 1 diabetes mellitus
por: Rui-Feng Mao, et al.
Publicado em: (2021-01-01)

Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.
por: Rubino, A, et al.
Publicado em: (2007)

Monitoring of adverse drug reactions in individuals with type 2 diabetes mellitus receiving oral hypoglycemic agents
por: Naiyer Shahzad
Publicado em: (2023-05-01)

Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study.
por: Nadia Gul, et al.
Publicado em: (2024-01-01)

Immunomodulatory agents and cell therapy for patients with type 1 diabetes
por: Melanie Rodacki, et al.
Publicado em: (2024-12-01)